Elucidation of the Molecular Mechanisms of Malignant Bone Tumors: Refining Diagnosis and Identifying Novel Targets for Treatment

Authors:
Jorge Casas-Ganem From the Orthopaedic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. Affiliated with Weill Medical College of Cornell University, and the Hospital for Special Surgery, New York, New York.

Search for other papers by Jorge Casas-Ganem in
Current site
Google Scholar
PubMed
Close
 MD
and
John H. Healey From the Orthopaedic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. Affiliated with Weill Medical College of Cornell University, and the Hospital for Special Surgery, New York, New York.
From the Orthopaedic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. Affiliated with Weill Medical College of Cornell University, and the Hospital for Special Surgery, New York, New York.

Search for other papers by John H. Healey in
Current site
Google Scholar
PubMed
Close
 MD
Full access

Primary bone tumors are rare, accounting for less than 0.2% of all cancers diagnosed yearly in the United States. Study of the molecular mechanisms of these diseases has given insight into their pathobiology. It has also identified molecular alterations that, if present, may be used in conjunction with histologic evaluation to further refine diagnosis, allowing cases to be stratified into prognostic groups more or less likely to show response to current cytotoxic protocols. Recent findings have lead to the identification of molecular pathways that may serve as targets of novel therapies, especially in the case of Ewing sarcoma. Telomere maintenance mechanisms are also emerging as potential targets for anticancer therapy. As the molecular mechanisms underlying malignant bone tumors are better understood, new anticancer agents targeting specific pathways are likely to emerge. This may make it possible to tailor treatment for each individual patient, using a combination of cytotoxic and targeted therapies based on the histologic and molecular profile of the patient's tumor.

Correspondence: John H. Healey, MD, Chief Orthopaedic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. E-mail: healeyj@mskcc.org
  • Collapse
  • Expand
  • 1

    Jemal A, Tiwari RC, Murray T et al.. Cancer statistics, 2004. CA Cancer J Clin 2004;54:829.

  • 2

    Gorlick R, Anderson P, Andrulis I et al.. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 2003;9:54425453.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422441.

  • 4

    Marec-Berard P, Philip T. Ewing sarcoma: the pediatrician's point of view. Pediatr Blood Cancer 2004;42:477480.

  • 5

    Huvos AG. Bone Tumors. Diagnosis, Treatment, and Prognosis, 2nd ed. Philadelphia, PA: W.B. Saunders Company; 1991.

  • 6

    Overholtzer M, Rao PH, Favis R et al.. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A 2003;100:1154711552.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 1997;79:15411547.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8

    Ladanyi M, Cha C, Lewis R et al.. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 1993;53:1618.

  • 9

    Wei G, Lonardo F, Ueda T et al.. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 1999;80:199204.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Man TK, Lu XY, Jaeweon K et al.. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 2004;4:45.

  • 11

    Moon RT, Brown JD, Torres M. WNTs modulate cell fate and behavior during vertebrate development. Trends Genet 1997;13:157162.

  • 12

    Hoang BH, Kubo T, Healey JH et al.. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004;109:106111.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Hoang BH, Kubo T, Healey JH et al.. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64:27342739.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Morris CD, Gorlick R, Huvos G et al.. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop 2001:5965.

  • 15

    Anninga JK, van de Vijver MJ, Cleton-Jansen AM et al.. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004;40:963970.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Khanna C, Wan X, Bose S et al.. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182186.

  • 17

    Ladanyi M, Lewis R, Garin-Chesa P et al.. EWS rearrangement in Ewing's sarcoma and peripheral neuroectodermal tumor. Molecular detection and correlation with cytogenetic analysis and MIC2 expression. Diagn Mol Pathol 1993;2:141146.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    de Alava E, Kawai A, Healey JH et al.. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998;16:12481255.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    de Alava E, Panizo A, Antonescu CR et al.. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma. Am J Pathol 2000;156:849855.

  • 20

    Ginsberg JP, de Alava E, Ladanyi M et al.. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol 1999;17:18091814.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Wei G, Antonescu CR, de Alava E et al.. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 15 2000;89:793799.

  • 22

    de Alava E, Antonescu CR, Panizo A et al.. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000;89:783792.

  • 23

    Ulaner GA, Hoffman AR, Otero J et al.. Divergent patterns of telomere maintenance mechanisms among human sarcomas: Sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004;41:155162.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Ulaner GA, Huang HY, Otero J et al.. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 2003;63:17591763.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Laverdiere C, Kolb EA, Supko JG et al.. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832840.

  • 26

    Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest 2003;21:167176.

  • 27

    Guo W, Healey JH, Meyers PA et al.. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999;5:621627.

  • 28

    Kolb EA, Kushner BH, Gorlick R et al.. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:34233430.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Uren A, Merchant MS, Sun CJ et al.. Beta-platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003;22:23342342.

  • 30

    Kelley MJ, Korczak JF, Sheridan E et al.. Familial chordoma, a tumor of notochordal remnants, is linked to chromosome 7q33. Am J Hum Genet 2001;69:454460.

  • 31

    Klingler L, Shooks J, Fiedler PN et al.. Microsatellite instability in sacral chordoma. J Surg Oncol 2000;73:100103.

  • 32

    Riva P, Crosti F, Orzan F et al.. Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 2003;107:493497.

  • 33

    Butler MG, Dahir GA, Hedges LK et al.. Cytogenetic, telomere, and telomerase studies in five surgically managed lumbosacral chordomas. Cancer Genet Cytogenet 1995;85:5157.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34

    Berven S, Zurakowski D, Mankin HJ et al.. Clinical outcome in chordoma: utility of flow cytometry in DNA determination. Spine 2002;27:374379.

  • 35

    Hruban RH, Traganos F, Reuter VE, Huvos AG. Chordomas with malignant spindle cell components: A DNA flow cytometric and immunohistochemical study with histogenetic implications. Am J Pathol 1990;137:435447.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36

    Casali PG, Messina A, Stacchiotti S et al.. Imatinib mesylate in chordoma. Cancer 2004;101:20862097.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 408 273 1
PDF Downloads 97 25 0
EPUB Downloads 0 0 0